<DOC>
	<DOCNO>NCT02901353</DOCNO>
	<brief_summary>A prospective , single-arm , multi-centre , observational , real world registry evaluate safety performance BioMime™ Morph Sirolimus Eluting Coronary Stent System long coronary lesion .</brief_summary>
	<brief_title>A Prospective , Single-arm , Multi-centre , Observational , Real World Registry</brief_title>
	<detailed_description>Title : A prospective , single-arm , multi-centre , observational , real world registry evaluate safety performance BioMime™ Morph Sirolimus Eluting Coronary Stent System long coronary lesion . Short Title : Morpheus - Global Registry Sponsor : Meril Life Sciences Pvt . Ltd Device Used : BioMime™ Morph Sirolimus Eluting Coronary Stent System Study population : The utilization BioMime™ Morph Sirolimus Eluting Coronary Stent System implantation long ( length ≤ 56 mm ) coronary lesion native coronary artery reference vessel diameter 2.25 mm 3.50 mm . Enrolment : Minimum 400 patient enrol Clinical Sites : Minimum 15 site Objectives : Purpose Registry evaluate safety performance BioMime™ Morph Sirolimus Eluting Coronary Stent System long ( length ≤ 56 mm ) coronary lesion native coronary artery reference vessel diameter 2.25 mm 3.50 mm . Study Design : This prospective , single-arm , multi-centre , observational , real world registry . All patient follow 24 month . Primary Outcome Measures : Freedom target lesion failure ( TLF ) 6 month 24 month TLF define composite cardiac death , myocardial infarction target lesion revascularization . Secondary Outcome Measures : 1 . MACE 1 , 6 , 12 24 month Defined composite cardiac death , myocardial infarction attribute target vessel Ischemia-driven TLR . 2 . Target vessel failure 1 , 6 , 12 24 month Defined cardiac death , myocardial infarction attribute target vessel , target vessel revascularization . 3 . Academic Research Consortium ( ARC ) define stent thrombosis 1 , 6 , 12 24 month . Definite , probable possible stent thrombosis acute , subacute , late late phase . Other Outcome Measures : 1 . Procedure Success : It define angiographic evidence &lt; 30 % final residual stenosis target lesion stent placement occurrence procedure relate MACE prior hospital discharge ( subject one lesion stented , bad case count ) 2 . Device Success : It define angiographic evidence &lt; 30 % final residual stenosis target lesion use assigned device</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . The patient must least 18 year age . 2 . Significant native coronary artery stenosis ( &gt; 50 % visual estimate ) lesion length ≤56mm . 3 . The patient guardian agree protocol requirement schedule followup provide informed write consent , approve appropriate Institutional Review Board/Ethical Committee respective clinical site 1 . Patients contraindicate follow medication : aspirin , heparin , clopidogrel , cobaltchromium , contrast agent sirolimus . 2 . An elective surgical procedure plan would necessitate interruption antiplatelet drug first 6 month post enrolment . 3 . Patients actively participate another drug device investigational study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>